Top Us Cannabis Stocks Right Now

Marijuana Market Leaders: Key U.S. Stocks to Follow in December 2023

As December 2023 approaches, the U.S. cannabis industry and top marijuana stocks continue to flourish, offering enticing opportunities for investors. Recent statistics forecast a significant growth trajectory for this sector. This growth is fueled by increasing legalization and public acceptance. The industry’s expansion is not just a temporary surge. It’s becoming a stable, long-term market segment.

For swing traders, the cannabis industry presents a dynamic landscape. Short-term price movements in cannabis stocks are influenced by regulatory news and market sentiment. This volatility can be profitable for experienced traders. They capitalize on these fluctuations. However, it requires careful analysis and timing.

Long-term investors are looking at the bigger picture. They focus on companies with robust business models and growth potential. These investors are less concerned with short-term volatility. They are more interested in the industry’s long-term trajectory. As the industry matures, these long-term investments could yield substantial returns. Optimistic market forecasts underscore the potential.

[Read More] Investing In Marijuana Stocks Here Are 3 To Know About

Top Performers in the U.S. Cannabis Sector for December 2023

  1. Trulieve Cannabis Corp. (OTC: TCNNF)
  2. Cresco Labs Inc. (OTC: CRLBF)

Trulieve Cannabis Corp.

Trulieve Cannabis Corp. is a prominent player in the U.S. cannabis industry. Founded in 2016, the company specializes in medical cannabis products. Their focus is on providing high-quality cannabis products and services. Trulieve has established a significant presence in the cannabis market. As of late 2023, Trulieve operates over 160 dispensaries across the United States. Their largest presence is in Florida, where they began. They have also expanded into several other states. These include California, Massachusetts, and Connecticut. Their rapid growth reflects their commitment to accessibility and quality.

Trulieve’s business model centers around vertical integration. This approach controls the entire process from cultivation to retail. It ensures product quality and consistency. Their product range is diverse, catering to various medical cannabis needs. They offer flower, edibles, concentrates, and topical products. Trulieve’s commitment to patient education and community involvement is noteworthy. In addition, they actively participate in community events and educational initiatives. This involvement strengthens their brand and customer loyalty. Their approach exemplifies a blend of business acumen and community responsibility.

Q3 2023 Financial and Operational Highlights

In the third quarter of 2023, Trulieve Cannabis Corp. reported significant financial and operational progress. The company generated $275 million in revenue, a remarkable 96% derived from retail sales. They achieved a substantial gross margin of 52%, resulting in a gross profit of $143 million. Despite a net loss of $25 million, the adjusted net loss was $15 million after excluding non-recurring charges. This adjustment reflects Trulieve’s strategic financial management. The company also reported an impressive EBITDA of $74 million and an adjusted EBITDA of $78 million. This performance underscores their operational efficiency and financial strength.

Operationally, Trulieve Cannabis Corp. made significant strides in expanding its market footprint. They experienced a 235% increase in Maryland traffic in the third quarter. This surge followed the launch of adult-use sales at their three dispensaries. The company also opened new dispensaries in Florida, Georgia, and Ohio while relocating others. This expansion brought their total retail locations to 190, with over 4 million square feet of cultivation and processing capacity. Their strategic expansion outside of Florida, constituting 32% of their retail locations, showcases their commitment to broadening their market presence.

TCNNF Stock Performance

TCNNF stock closed on November 29th   at $5.41, up 40.52% in the last month of trading. In this case, the stock has a 52-week price range of $3.42-$16.11 and is down 28.53% year to date. According to analysts at CNN Business, TCNNF stock has a 12-month average price target of $11.82 per share. In this case, this represents an upside of 118.48% from its last trading price of 5.41.

[Read More] GreenTech Innovators: Leading the Charge in Ancillary Cannabis Stocks for 2023

Cresco Labs Inc.

Cresco Labs Inc. is a notable name in the American cannabis industry. Established in 2013, the company focuses on medical and recreational cannabis products. Cresco Labs is renowned for its commitment to quality, safety, and innovation. This commitment is evident in their diverse product portfolio. As of late 2023, Cresco Labs operates over 45 dispensaries nationwide. Their most significant presence is in Illinois, Pennsylvania, and Ohio. These states represent key markets for the company. Cresco Labs has also expanded into several other states. This expansion showcases their strategic growth in the cannabis sector.


The company’s business model emphasizes both retail and wholesale operations. This approach allows for a broad market reach. Cresco Labs offers a wide range of cannabis products. These include flower, edibles, concentrates, and topicals. Their focus on consumer education and safety sets them apart. Cresco Labs actively engages in community outreach and education programs. They aim to destigmatize cannabis use. This approach reflects their dedication to responsible and informed consumption. Cresco Labs continues to grow as a leader in the U.S. cannabis market.

Third Quarter 2023 Financial Highlights

Cresco Labs Inc. reported a robust third quarter in 2023, with significant financial and operational achievements. The company’s revenue reached $191 million, driven by retail growth and strong performance in core markets. This success was despite divesting certain assets as part of their strategic focus. They have made remarkable improvements since the beginning of their Year-of-the-Core strategy in Q1. Adjusted gross margin increased by over 480 basis points, while adjusted SG&A decreased by $40 million annually. The adjusted EBITDA margin rose impressively by over 1000 basis points. Cresco Labs also reported a gross profit of $94 million, representing 49% of their revenue. Their operating cash flow for the first nine months was a solid $62 million.

Operationally, Cresco Labs strengthened its market position in the third quarter of 2023. They retained the number one share position in Illinois, Pennsylvania, and Massachusetts. Their portfolio remains the industry leader in branded flower and concentrates. It also ranks fourth in branded vapes and edibles. The branded equivalized unit volume surged by 28% year-over-year to 20 million. Retail transactions saw a 17% increase from the previous year, totaling 1.4 million. Cresco Labs expanded its retail presence, opening two new Sunnyside stores in Florida. By September 30, 2023, their nationwide store count reached 70, marking significant growth and expansion in the retail sector.

CRLBF Stock Performance

CRLBF shares finished on November 29th  at $1.72, up 48.28% in the last month of trading. The stock is presently trading in a 52-week price range of $1.00-$4.20, showing a 4.42% decrease year to date. According to analysts at CNN Business, CRLBF stock has a 12-month median price target of $2.81 per share. In this case, this represents an increase of 63.37% from its last trading price of $1.72.

[Read More] Elevate Your Portfolio: December 2023’s Must-Watch US Marijuana Stocks

High Potential: December 2023’s Leading U.S. Marijuana Market Movers

The third quarter of 2023 has been a period of significant growth and strategic advancement for leading cannabis companies like Trulieve Cannabis Corp. and Cresco Labs Inc. Trulieve’s impressive expansion, with over 190 retail dispensaries and a substantial increase in Maryland traffic, underscores its dominance in the U.S. cannabis market. In addition, their financial performance, marked by a revenue of $275 million and a robust EBITDA, reflects a strong operational framework and a focus on long-term growth. Similarly, Cresco Labs has demonstrated remarkable financial and operational strength. With a revenue of $191 million and a gross profit of $94 million, Cresco Labs has solidified its position in core markets like Illinois, Pennsylvania, and Massachusetts. Their strategic initiatives, including the Year-of-the-Core strategy, have significantly enhanced profitability and market share, positioning them as a leader in the cannabis industry.

These achievements highlight the dynamic nature of the cannabis sector in the U.S. Both Trulieve and Cresco Labs have navigated the complexities of the market with agility and foresight, adapting to changing regulations and consumer preferences. In general, their expansion into new states and the successful launch of new products and dispensaries reflect a deep understanding of market demands. Overall, as the industry continues to evolve, these companies are well-positioned to capitalize on emerging opportunities and continue their trajectory of growth. Their success stories serve as a testament to the potential of the U.S. cannabis industry, which is rapidly becoming a significant contributor to the national economy.

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 |
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like